rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant. GLP-1 is a naturally occurring... GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake.
- Mechanism
- Curator reviewed
These rGLP-1 mimetics bind to rGLP-1 receptors with similar affinity and produce biological actions identical to those of native rGLP-1 which controls blood glucose via multiple actions including stimulation of insulin secretion and inhibition of both glucagon secretion and gastric emptying. Preclinical data suggest that rGLP-1 analogs engage signaling pathways in the islet beta-cell that lead to stimulation of beta-cell replication and inhibition of beta-cell apoptosis.
- Primary indication
- Investigated for use/treatment in congestive heart failure and diabetes mellitus type 2.Curator reviewed
What you can answer from here — as of April 02, 2025
Which companies are running trials of rGLP-1, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account